TCM
ARCT icon

Traynor Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Traynor Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,939
Closed -$243K – 158
2020
Q3 		$243K Buy
+4,939
New +$245K 0.06% 126

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Traynor Capital Management's ARCT Position: Q4 2020 in Review

Traynor Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2020, closing a stake of 4,939 shares — an estimated $243K sold.

Traynor Capital Management first reported a position in ARCT in Q3 2020 and held it in 1 quarter. The position peaked at $243K in Q3 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q4 2020.

  • Traynor Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Traynor Capital Management sold 4,939 Arcturus Therapeutics shares in Q4 2020, an estimated $243K.
  • Traynor Capital Management first reported a position in Arcturus Therapeutics in Q3 2020 and held it in 1 quarter.
  • Traynor Capital Management's Arcturus Therapeutics position peaked at $243K in Q3 2020.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2020.

Based on Traynor Capital Management's 13F filing for Q4 2020, filed 14 Jan 2021.